university of puck (@uofpuck) 's Twitter Profile
university of puck

@uofpuck

ID: 3469261822

linkhttp://universityofpuck.com calendar_today28-08-2015 14:14:03

262 Tweet

34 Followers

351 Following

university of puck (@uofpuck) 's Twitter Profile Photo

I don’t understand the market?! How does $TRIL announcing the dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia get a negative response from market? Heading down…$9.55??

university of puck (@uofpuck) 's Twitter Profile Photo

Wtf? Can someone explain this precipitous drop in $TRIL? It makes no sense? They announce positive single agent activity, combo activity, activity in both sold and liquid tumors, add a veteran M&A expert to the board and announce FPI for ph1b/2 and still the market shits on it?!

Tril_Investor (@tril_investor) 's Twitter Profile Photo

Maybe I should have kept posting as I think $PFE got $TRIL a bit too cheap (but like it wouldn't have made a big difference on stock price). I have however earned well on these shares and I expect (and hope) these $TRIL #CD47 drugs will benefit many cancer patients in the future.

Verastem Oncology (@verastemoncolog) 's Twitter Profile Photo

We’re honored to be supporting STAAR OC Foundation’s Step Up America for Ovarian Cancer to help bring awareness to #lowgradeserous #ovariancancer. #ColorItTeal

We’re honored to be supporting STAAR OC Foundation’s Step Up America for Ovarian Cancer to help bring awareness to #lowgradeserous #ovariancancer. #ColorItTeal
Corinne McGrath (@corinnedmcgrath) 's Twitter Profile Photo

Coastal Carolina's hockey team is 3-1 to start the season, which may be surprising for some since they have to drive nearly two hours away just to get on some ice. It's the dedication and brotherhood which has led this team to back-to-back ACCHL titles. @CCU_Hockey

Verastem Oncology (@verastemoncolog) 's Twitter Profile Photo

Our CSO Jon Pachter looks forward to presenting on how the RAF/MEK clamp avutometinib enhances antitumor efficacy of KRAS G12C and G12D inhibitors at the upcoming AACR Special Conference on Targeting RAS.

Verastem Oncology (@verastemoncolog) 's Twitter Profile Photo

Introducing Let’s Talk About LGSOC, a new initiative to support broader awareness, education, and support for patients living with #LGSOC, a rare and often misunderstood form of ovarian cancer. Visit this website to learn more: letstalkaboutlgsoc.com

Verastem Oncology (@verastemoncolog) 's Twitter Profile Photo

This #WomensHealthMonth, follow our journey to support patients, advocacy organizations, and researchers working to raise awareness and educate others about #LGSOC, a rare and often misunderstood form of ovarian cancer. Visit LetsTalkAboutLGSOC.com to learn more.

Verastem Oncology (@verastemoncolog) 's Twitter Profile Photo

#ANNOUNCEMENT: We're proud to announce the appointment of Karin Tollefson, SVP & Head of Global Medical Affairs @SeagenGlobal, to our Board of Directors. Learn more here: bit.ly/4305NcN

#ANNOUNCEMENT: We're proud to announce the appointment of Karin Tollefson, SVP & Head of Global Medical Affairs @SeagenGlobal, to our Board of Directors. Learn more here: bit.ly/4305NcN
Verastem Oncology (@verastemoncolog) 's Twitter Profile Photo

“I firmly believe that by bridging innovative research with robust community engagement, we create an empowering environment where those impacted by #lowgradeserous #ovariancancer feel heard, understood & supported.” Hear more from $VSTM CEO Dan Paterson bit.ly/3u94UCA